Fluicell AB Cash Flow Conversion Efficiency
Fluicell AB cash flow conversion efficiency. Based on the latest financial reports, Fluicell AB (FLUI) has a cash flow conversion efficiency ratio of 0.017x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr248.00K ≈ $26.69K USD) by net assets (Skr14.21 Million ≈ $1.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fluicell AB (2016–2025)
Cash flow conversion efficiency of Fluicell AB from 2016 to 2025. This chart illustrates how Fluicell AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View FLUI stock price for real-time trading data and today's change.
Fluicell AB Cash Flow Conversion Ratio Explained
Fluicell AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fluicell AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluicell AB ranked by their cash flow conversion efficiency. Also see Fluicell AB (FLUI) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adneo Ltd
AU:AD1
|
0.522x |
|
REY Resources Ltd
AU:REY
|
-0.165x |
|
ModivCare Inc
NASDAQ:MODV
|
0.937x |
|
Inspire Veterinary Partners, Inc.
NASDAQ:IVP
|
-0.308x |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
0.005x |
|
Pragma Inkaso S.A.
WAR:PRI
|
-0.061x |
|
Largo SAS
PA:ALLGO
|
3.901x |
|
Revelation Biosciences Inc
NASDAQ:REVB
|
-0.254x |
Annual Cash Flow Conversion Efficiency for Fluicell AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Fluicell AB from 2016 to 2025. Review cash generation quality of Fluicell AB to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr10.90 Million ≈ $1.17 Million |
Skr-4.95 Million ≈ $-532.16K |
-0.454x | +44.32% |
| 2024-12-31 | Skr19.23 Million ≈ $2.07 Million |
Skr-15.67 Million ≈ $-1.69 Million |
-0.815x | +98.73% |
| 2023-12-31 | Skr425.00K ≈ $45.74K |
Skr-27.23 Million ≈ $-2.93 Million |
-64.064x | -7037.92% |
| 2022-12-31 | Skr23.45 Million ≈ $2.52 Million |
Skr-21.04 Million ≈ $-2.26 Million |
-0.898x | +7.98% |
| 2021-12-31 | Skr19.11 Million ≈ $2.06 Million |
Skr-18.64 Million ≈ $-2.01 Million |
-0.975x | -8.24% |
| 2020-12-31 | Skr19.50 Million ≈ $2.10 Million |
Skr-17.57 Million ≈ $-1.89 Million |
-0.901x | +46.02% |
| 2019-12-31 | Skr10.22 Million ≈ $1.10 Million |
Skr-17.07 Million ≈ $-1.84 Million |
-1.669x | -213.09% |
| 2018-12-31 | Skr23.37 Million ≈ $2.52 Million |
Skr-12.46 Million ≈ $-1.34 Million |
-0.533x | +34.76% |
| 2017-12-31 | Skr9.58 Million ≈ $1.03 Million |
Skr-7.83 Million ≈ $-842.74K |
-0.817x | +72.63% |
| 2016-12-31 | Skr1.84 Million ≈ $198.12K |
Skr-5.50 Million ≈ $-591.56K |
-2.986x | -- |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more